Bristol-Myers Squibb Aktie News

Bristol-Myers Squibb Company ( BMY ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Chuck Triano Christopher Boerner - CEO & Chairman David Elkins - Executive VP & CFO Cristian Massacesi - Executive VP, Chief Medical Officer & Head of Development Adam Lenkowsky - Executive VP & Chief Commercialization Officer Conference Call Participants Christopher Schott - JPMorgan Ch...

Bristol-Myers Squibb Company's Q3 earnings are out - beating analyst's estimates - and for once, stock is buoyant (in trading so far today). BMY faces significant challenges as major drugs lose patent protection, leading to revenue declines despite a strong dividend yield. Recent acquisitions and new product launches have underperformed versus management's ambitious targets, raising concerns ab...

The article analyzes the top large-cap value (GASV) stocks using YCharts' Value Score and Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Ten of eighteen 'safer' lowest-priced GASV stocks, including ET, MPLX, YRD, VZ, BMY, TFC, T, SU, MFC, and BBVA, are considered buyable in October. Analyst projections suggest the top ten GASV stocks could deliver average net gai...

While many seniors have enjoyed a long bull market over the past 35 years, there is a point when income becomes more critical than stock appreciation.

While total revenue grew in the quarter, competition weighed on the drugmaker's legacy portfolio.

Bristol Myers Squibb added nearly $1 billion to its bottom line in the third quarter as costs came down and revenue climbed on the strength of its newer drugs.

Bristol Myers Squibb beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its cancer immunotherapy and blood thinner Eliquis helped the drugmaker overcome a hit from generic competition for several older drugs.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Third Quarter Financial Results for 2025.